344 related articles for article (PubMed ID: 24373113)
1. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
J Med Econ; 2015 Jan; 18(1):56-68. PubMed ID: 25271378
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
Evans M; Chubb B; Gundgaard J
Diabetes Ther; 2017 Apr; 8(2):275-291. PubMed ID: 28210866
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.
Lane WS; Weatherall J; Gundgaard J; Pollock RF
J Med Econ; 2018 Feb; 21(2):144-151. PubMed ID: 28945173
[TBL] [Abstract][Full Text] [Related]
7. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
Weatherall J; Bloudek L; Buchs S
Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
[TBL] [Abstract][Full Text] [Related]
10. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
12. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.
Woehl A; Evans M; Tetlow AP; McEwan P
Cardiovasc Diabetol; 2008 Aug; 7():24. PubMed ID: 18694484
[TBL] [Abstract][Full Text] [Related]
15. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.
Evans M; McEwan P; Foos V
J Med Econ; 2015 Feb; 18(2):96-105. PubMed ID: 25325179
[TBL] [Abstract][Full Text] [Related]
16. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å; Lundqvist A
Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
[TBL] [Abstract][Full Text] [Related]
19. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
